ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 46.2 | 35.4 | 7.2 |
| Other income | 0.1 | 0.1 | 0.0 |
| Total income | 46.3 | 35.5 | 7.2 |
| Profit before exceptional items & tax | 2.8 | 1.4 | -0.5 |
| Profit before tax | 2.8 | 1.4 | -0.5 |
| Net profit | 2.1 | 1.1 | -0.5 |
| Operating margin | 6.0% | 3.9% | -6.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +90.90% |
|---|---|
| Revenue, year on year | +541.70% |
| Operating profit, year on year | +640.00% |
| Operating profit, quarter on quarter | +107.70% |
BSE results filing, NSE: KABRADG. Figures extracted from the filing.
Kabra Drugs Ltd: key numbers
- Share price
- ₹18.15
- Market cap
- ₹43.03 Cr
- Revenue (annual)
- ₹92.74 Cr
- Net profit (annual)
- ₹4.96 Cr
- P/E (TTM)
- 5.6×Sector 43.8×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kabra Drugs Ltd
All →Kabra Drugs Q2 FY27 Results: Net Profit ₹1.9 Cr, Up 5.6% YoY
Kabra Drugs Ltd reported revenue from operations of ₹32 Cr (+61.6% YoY) and net profit of ₹1.9 Cr (+5.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.9 Cr · +5.6% YoY
Kabra Drugs Board Meeting Date
Kabra Drugs (now Aanjaay Industries) intimated a board meeting on 6 November 2026 to consider unaudited results for the quarter ended 30 September 2026. The filing is advance notice only.
Kabra Drugs Other Announcement
The company has filed its quarterly shareholding pattern for the period ending September 30, 2026. The document discloses the distribution of shareholding among various categories of investors.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited conducted its 37th Annual General Meeting on September 30, 2026. Shareholders transacted business including the adoption of financial statements and director appointments.
Kabra Drugs Annual Report
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.